

# CONTENTS

---

KEY MESSAGES FROM THIS REPORT		1
SUMMARY OF KEY DATA		3
	International pharmaceutical R&D expenditure and sales	3
	Products in the pipeline	4
	Submission, authorisation & marketing activity	5
INTRODUCTION AND OBJECTIVE		9
	Changes for survey on 1997 activities	9
	Changes made to questionnaires for collection of data relating to 1997 activities	10
METHODOLOGY		13
	Response rate	13
	Analyses	13
SECTION 1: INTERNATIONAL PHARMACEUTICAL R&D EXPENDITURE AND SALES		15
	Methodology	17
	Response and analyses	17
	List of figures	19
	Definitions	20
	Discussion	45
Section 2: PRODUCTS IN THE PIPELINE		47
	Methodology	49
	New active substances in active clinical development	49
	International Marketed Medicines Database	50
	Therapeutic areas	50
	Data on attrition	50
	List of figures	51
	Definitions	52
	Discussion	71
SECTION 3: NAS SUBMISSION, AUTHORISATION & MARKETING ACTIVITY		75
	Methodology	77
	Analyses	77

	<i>Continued...</i>	
--	---------------------	--

---

	List of figures	78
	Definitions	79
	Discussion	92
FUTURE WORK		94
ACKNOWLEDGEMENT		95
REFERENCES		97
APPENDIX 1 : Pharmaceutical companies invited to participate		101
APPENDIX 2 : <i>International Pharmaceutical R&amp;D Expenditure and Sales</i> questionnaire		103
APPENDIX 3 : <i>Products in the pipeline</i> questionnaire		105
APPENDIX 4: <i>New active substance: submission, authorisation and marketing activity</i> questionnaire		107
APPENDIX 5 : OECD mean exchange rates		109
APPENDIX 6 : New molecular entities first launched on to the world market in 1997		111
APPENDIX 7 : Data Tables		117
	Section 1: International pharmaceutical R&D expenditure and sales	117
	Section 2: Products in the clinical development pipeline	129
	Section 3: New active substance activity: submission, authorisation and marketing	137